STD Diagnostics Market By Std Type (Herpes Simplex Virus (HSV) Testing, Chancroid Testing, Human Papilloma Virus (HPV) Testing, P&S Syphilis Testing, Human Immunodeficiency Virus (HIV) Testing, Gonorrhea Testing, Chlamydia Testing), By Testing Device (Laboratory Testing Devices, Point Of Care Testing Devices), By Location Of Testing (Point-Of-Care (POC) Testing, Laboratory Testing), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: May 4, 2016

Key Findings


The global STD diagnostics market is currently valued at $100 billion which is anticipated to grow beyond $200 billion with a compounded annual growth rate of 8.9% during the forecasted period 2015to 2022. The increase in patient’s awareness and growing government initiatives are driving the growth of the market. Moreover, increasing population who prefer to have multiple sex partners is boosting the growth of the market. Advanced technology in diagnostics market are providing more precise result because of significant shift from traditional laboratories to rapid changing hi-tech laboratories which is also fueling the growth in the STD diagnostics market. Improvements in healthcare infrastructure and rise in per capita income are the major factors driving the health care reform and at the same time such reforms are promoting the investments for STD diagnostics market. One of the common diagnostics isChlamydia testing in STDS which alone accounts for over 34% of the market share. Andlaboratory testing devices is estimated to dominate the revenue generation market by $67.9 million.


Market Segment Insight


The whole market is mainly segmented as STD type, by testing devices and by location of testing. By the types, STD market is further segmented as Herpes Simplex Virus (HSV) testing, Chancroid testing, Human Papilloma Virus (HPV) testing P&S Syphilis testing, Human Immunodeficiency Virus (HIV) testing, Gonorrhea testing and Chlamydia testing. Chlamydia testing is strictly recommended by the U.S. governments Preventive Services Task Force (PSTF) for the girls who are below 25 years and are sexually active. Compounded annual growth rate for chlamydia alone is estimated 10% for the forecasted period. On the basis of location of testing the markets is segmented into laboratory testing and point-of- care testing. With the increasing population and HIV and HPVs diseases, diagnostics market is shifting towards point-of-care more.


Regional Insight


Geographically the market is segmented into North America, Europe, APAC and RoW. North America holds the largest market share and it is the fastest growing region followed by Asia Pacific, Europe and RoW during the forecasted period. Growth of the industry is represented as the increase in the adoption of technologically advanced products. The global sexually transmitted diseases diagnostics market is dominated by North America due to the presence of public healthcare insurance plans fostering healthcare concern amongst people. Moreover, availability of FDA-approved advanced sexually transmitted diseases testing devices is also boosting the market growth. Asia Pacific accounts for approx. 22% of the total share. The majordriving factors includes the increasing prevalence of sexually transmitted infections in the underdeveloped countries of Asia Pacific as well as the economic prosperity in these regions is also supporting the growth of sexually transmitted diseases diagnostics market


Competitive Insight


Some of the major prominent player in the global diagnostics testing market are BioMerieux, Bio-Rad, Enzo Biochem, ID Biomedical/GSK, Qiagen, Roche, Scienion Sequenom and Abbott etc.

CHAP 1. METHODOLOGY & SCOPE 14
1.1. RESEARCH METHODOLOGY 14
1.2. RESEARCH SCOPE & ASSUMPTIONS 14
1.3. LIST OF DATA SOURCES 14


CHAP 2. EXECUTIVE SUMMARY 15
2.1. GLOBAL STD DIAGNOSTIC MARKET SUMMARY & KEY BUYING CRITERIA 15
2.2. GLOBAL STD DIAGNOSTIC MARKET OUTLOOK 15
2.3. MARKET SEGMENTATION ANALYSIS 15
2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 15
2.5. GLOBAL STD DIAGNOSTIC MARKET VALUE CHAIN ANALYSIS 15
2.6. VENDOR LANDSCAPE 15


CHAP 3. GLOBAL STD DIAGNOSTIC MARKET 16
3.1. MARKET DRIVER ANALYSIS 16
3.1.1. GROWING INCIDENCE RATES AND INCREASING PREVALENCE RATES OF STD 16
3.1.2. IMPLEMENTATION OF NATIONAL SCREENING PROGRAMS 16
3.1.3. SUPPORTING REIMBURSEMENT FOR STDS TESTING 16
3.2. MARKET RESTRAINT ANALYSIS 16
3.2.1. SOCIAL STIGMA ASSOCIATED WITH PATIENTS VISITING SPECIALIZED STD CLINICS 16
3.2.2. HUGE PROPORTION OF PATIENTS INFECTED WITH STDS IN OUT-OF-REACH GEOGRAPHIC AREAS 16
3.2.3. STRINGENT REGULATORY ABIDANCE REQUIREMENTS FOR THE PARTICIPANTS OF STD MARKET 16
3.3. KEY OPPORTUNITIES 16
3.3.1. DECREASING NUMBER OF VISITS TO GUM CLINICS AND SPECIALIZED STD CLINICS 16
3.3.2. NATIONAL SCREENING PROGRAMS ACROSS THE GLOBE 16
3.3.3. NICHE OPPORTUNITIES FOR TECHNOLOGY AND POC TEST PROVIDERS IN AN EMERGING ECONOMIES 16
3.4. CHALLENGES 16
3.4.1. TURNING PEOPLE FOR DIAGNOSTICS ST0064 CENTERS 16


CHAP 4. INDUSTRY ANALYSIS 17
4.1. GLOBAL STD DIAGNOSTIC MARKET– PORTER’S FIVE FORCE MODEL 17
4.2. GLOBAL STD DIAGNOSTIC MARKET– PESTEL ANALYSIS 17
4.3. GLOBAL STD DIAGNOSTIC MARKET– GAP ANALYSIS 17


CHAP 5. GLOBAL STD DIAGNOSTIC MARKET BY STD TYPE 2012-2022 ($ BILLION) 18
5.1. GLOBAL STD DIAGNOSTIC MARKET BY HERPES SIMPLEX VIRUS (HSV) TESTING 2012-2022 ($ BILLION) 18
5.2. GLOBAL STD DIAGNOSTIC MARKET BY CHANCROID TESTING 2012-2022 ($ BILLION) 18
5.3. GLOBAL STD DIAGNOSTIC MARKET BY HUMAN PAPILLOMA VIRUS (HPV) TESTING 2012-2022 ($ BILLION) 18
5.4. GLOBAL STD DIAGNOSTIC MARKET BY P&S SYPHILIS TESTING 2012-2022 ($ BILLION) 18
5.5. GLOBAL STD DIAGNOSTIC MARKET BY HUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING 2012-2022 ($ BILLION) 18
5.6. GLOBAL STD DIAGNOSTIC MARKET BY GONORRHEA TESTING 2012-2022 ($ BILLION) 18
5.7. GLOBAL STD DIAGNOSTIC MARKET BY CHLAMYDIA TESTING 2012-2022 ($ BILLION) 18


CHAP 6. GLOBAL STD DIAGNOSTIC MARKET BY TESTING DEVICE 2012-2022 ($ BILLION) 19
6.1. GLOBAL STD DIAGNOSTIC MARKET BY LABORATORY TESTING DEVICES 2012-2022 ($ BILLION) 19
6.1.1. GLOBAL STD DIAGNOSTIC MARKET BY PCRS 2012-2022 ($ BILLION) 19
6.1.2. GLOBAL STD DIAGNOSTIC MARKET BY IMMUNOCHROMATOGRAPHIC CAPILLARY FLOW DIPSTICK TECHNOLOGY (ASSAY) 2012-2022 ($ BILLION) 19
6.1.3. GLOBAL STD DIAGNOSTIC MARKET BY FLOW CYTOMETERS 2012-2022 ($ BILLION) 19
6.1.4. GLOBAL STD DIAGNOSTIC MARKET BY DIFFERENTIAL LIGHT SCATTERING 2012-2022 ($ BILLION) 19
6.1.5. GLOBAL STD DIAGNOSTIC MARKET BY ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 2012-2022 ($ BILLION) 19
6.2. GLOBAL STD DIAGNOSTIC MARKET BY POINT OF CARE TESTING DEVICES 2012-2022 ($ BILLION) 19
6.2.1. GLOBAL STD DIAGNOSTIC MARKET BY PHONE CHIPS 2012-2022 ($ BILLION) 19
6.2.2. GLOBAL STD DIAGNOSTIC MARKET BY MICROFLUIDICS 2012-2022 ($ BILLION) 19
6.2.3. GLOBAL STD DIAGNOSTIC MARKET BY IMMUNOCHROMATOGRAPHIC TESTS (ICTS) 2012-2022 ($ BILLION) 19
6.2.4. GLOBAL STD DIAGNOSTIC MARKET BY RAPID DIAGNOSTIC KITS 2012-2022 ($ BILLION) 19


CHAP 7. GLOBAL STD DIAGNOSTIC MARKET BY LOCATION OF TESTING 2012-2022 ($ BILLION) 20
7.1. GLOBAL STD DIAGNOSTIC MARKET BY POINT-OF-CARE (POC) TESTING 2012-2022 ($ BILLION) 20
7.2. GLOBAL STD DIAGNOSTIC MARKET BY LABORATORY TESTING 2012-2022 ($ BILLION) 20
7.2.1. GLOBAL STD DIAGNOSTIC MARKET BY COMMERCIAL LABORATORY TESTING 2012-2022 ($ BILLION) 20
7.2.2. GLOBAL STD DIAGNOSTIC MARKET BY PRIVATE LABORATORY TESTING 2012-2022 ($ BILLION) 20
7.2.3. GLOBAL STD DIAGNOSTIC MARKET BY PUBLIC LABORATORY TESTING 2012-2022 ($ BILLION) 20


CHAP 8. GLOBAL STD DIAGNOSTIC MARKET REGIONAL OUTLOOK 2012-2022 ($ BILLION) 21
8.1. GLOBAL STD DIAGNOSTIC MARKET BY REGION 2012-2022 ($ BILLION) 21
8.2. NORTH AMERICA 21
8.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
8.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 21
8.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
8.2.3.1. U.S. 21
8.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
8.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
8.2.3.2. CANADA 21
8.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
8.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
8.2.3.3. MEXICO 21
8.2.3.3.1. MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
8.2.3.3.2. MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
8.3. EUROPE 22
8.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
8.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 22
8.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
8.3.3.1. GERMANY 22
8.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
8.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
8.3.3.2. UK 22
8.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
8.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
8.3.3.3. FRANCE 22
8.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
8.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
8.3.3.3.3. SPAIN 23
8.3.3.3.4. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
8.3.3.3.5. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
8.3.3.3.6. ITALY 23
8.3.3.3.7. ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
8.3.3.3.8. ITALY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
8.3.3.4. REST OF EUROPE 23
8.3.3.4.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 23
8.3.3.4.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 23
8.4. ASIA PACIFIC 23
8.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
8.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 23
8.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
8.4.3.1. CHINA 23
8.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
8.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
8.4.3.2. INDIA 23
8.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
8.4.3.3. JAPAN 24
8.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 24
8.4.3.4. AUSTRALIA 24
8.4.3.4.1. AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.4.3.4.2. AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 24
8.4.3.5. OTHERS 24
8.4.3.5.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 24
8.4.3.5.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 24
8.5. REST OF THE WORLD 24
8.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
8.5.3. SOUTH AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
8.5.4. SOUTH AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24


CHAP 9. COMPETITIVE LANDSCAPE 25
9.1. ABBOTT 26
9.1.1. COMPANY OVERVIEW 26
9.1.2. SCOT ANALYSIS 26
9.1.3. PRODUCT BENCHMARKING 26
9.1.4. STRATEGIC INITIATIVES 26
9.2. BECKMAN COULTER/DANAHER 26
9.2.1. COMPANY OVERVIEW 26
9.2.2. SCOT ANALYSIS 26
9.2.3. PRODUCT BENCHMARKING 26
9.2.4. STRATEGIC INITIATIVES 26
9.3. BECTON DICKINSON 26
9.3.1. COMPANY OVERVIEW 26
9.3.2. SCOT ANALYSIS 26
9.3.3. PRODUCT BENCHMARKING 26
9.3.4. STRATEGIC INITIATIVES 26
9.4. BIOMERIEUX 26
9.4.1. COMPANY OVERVIEW 26
9.4.2. SCOT ANALYSIS 26
9.4.3. PRODUCT BENCHMARKING 26
9.4.4. STRATEGIC INITIATIVES 26
9.5. BIO-RAD 26
9.5.1. COMPANY OVERVIEW 26
9.5.2. SCOT ANALYSIS 26
9.5.3. PRODUCT BENCHMARKING 26
9.5.4. STRATEGIC INITIATIVES 26
9.6. ENZO BIOCHEM 26
9.6.1. COMPANY OVERVIEW 26
9.6.2. SCOT ANALYSIS 27
9.6.3. PRODUCT BENCHMARKING 27
9.6.4. STRATEGIC INITIATIVES 27
9.7. ID BIOMEDICAL/GSK 27
9.7.1. COMPANY OVERVIEW 27
9.7.2. SCOT ANALYSIS 27
9.7.3. PRODUCT BENCHMARKING 27
9.7.4. STRATEGIC INITIATIVES 27
9.8. QIAGEN 27
9.8.1. COMPANY OVERVIEW 27
9.8.2. SCOT ANALYSIS 27
9.8.3. PRODUCT BENCHMARKING 27
9.8.4. STRATEGIC INITIATIVES 27
9.9. ROCHE 27
9.9.1. COMPANY OVERVIEW 27
9.9.2. SCOT ANALYSIS 27
9.9.3. PRODUCT BENCHMARKING 27
9.9.4. STRATEGIC INITIATIVES 27
9.10. SCIENION 27
9.10.1. COMPANY OVERVIEW 27
9.10.2. SCOT ANALYSIS 27
9.10.3. PRODUCT BENCHMARKING 27
9.10.4. STRATEGIC INITIATIVES 27
9.11. SEQUENOM 27
9.11.1. COMPANY OVERVIEW 27
9.11.2. SCOT ANALYSIS 27
9.11.3. PRODUCT BENCHMARKING 27
9.11.4. STRATEGIC INITIATIVES 27
9.12. SERACARE 28
9.12.1. COMPANY OVERVIEW 28
9.12.2. SCOT ANALYSIS 28
9.12.3. PRODUCT BENCHMARKING 28
9.12.4. STRATEGIC INITIATIVES 28
9.13. SIEMENS 28
9.13.1. COMPANY OVERVIEW 28
9.13.2. SCOT ANALYSIS 28
9.13.3. PRODUCT BENCHMARKING 28
9.13.4. STRATEGIC INITIATIVES 28
9.14. THERMO FISHER 28
9.14.1. COMPANY OVERVIEW 28
9.14.2. SCOT ANALYSIS 28
9.14.3. PRODUCT BENCHMARKING 28
9.14.4. STRATEGIC INITIATIVES 28
9.15. WAKO 28
9.15.1. COMPANY OVERVIEW 28
9.15.2. SCOT ANALYSIS 28
9.15.3. PRODUCT BENCHMARKING 28
9.15.4. STRATEGIC INITIATIVES 28

TABLE 1 GLOBAL STD DIAGNOSTIC MARKET BY STD TYPE 2012-2022 ($ BILLION) 28
TABLE 2 GLOBAL STD DIAGNOSTIC MARKET BY HERPES SIMPLEX VIRUS (HSV) TESTING 2012-2022 ($ BILLION) 28
TABLE 3 GLOBAL STD DIAGNOSTIC MARKET BY CHANCROID TESTING 2012-2022 ($ BILLION) 28
TABLE 4 GLOBAL STD DIAGNOSTIC MARKET BY HUMAN PAPILLOMA VIRUS (HPV) TESTING 2012-2022 ($ BILLION) 29
TABLE 5 GLOBAL STD DIAGNOSTIC MARKET BY P&S SYPHILIS TESTING 2012-2022 ($ BILLION) 29
TABLE 6 GLOBAL STD DIAGNOSTIC MARKET BY HUMAN IMMUNODEFICIENCY VIRUS (HIV) TESTING 2012-2022 ($ BILLION) 29
TABLE 7 GLOBAL STD DIAGNOSTIC MARKET BY GONORRHEA TESTING 2012-2022 ($ BILLION) 29
TABLE 8 GLOBAL STD DIAGNOSTIC MARKET BY CHLAMYDIA TESTING 2012-2022 ($ BILLION) 29
TABLE 9 GLOBAL STD DIAGNOSTIC MARKET BY TESTING DEVICE 2012-2022 ($ BILLION) 29
TABLE 10 GLOBAL STD DIAGNOSTIC MARKET BY LABORATORY TESTING DEVICES 2012-2022 ($ BILLION) 29
TABLE 11 GLOBAL STD DIAGNOSTIC MARKET BY PCRS 2012-2022 ($ BILLION) 29
TABLE 12 GLOBAL STD DIAGNOSTIC MARKET BY IMMUNOCHROMATOGRAPHIC CAPILLARY FLOW DIPSTICK TECHNOLOGY (ASSAY) 2012-2022 ($ BILLION) 29
TABLE 13 GLOBAL STD DIAGNOSTIC MARKET BY FLOW CYTOMETERS 2012-2022 ($ BILLION) 29
TABLE 14 GLOBAL STD DIAGNOSTIC MARKET BY DIFFERENTIAL LIGHT SCATTERING 2012-2022 ($ BILLION) 29
TABLE 15 GLOBAL STD DIAGNOSTIC MARKET BY ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA) 2012-2022 ($ BILLION) 29
TABLE 16 GLOBAL STD DIAGNOSTIC MARKET BY POINT OF CARE TESTING DEVICES 2012-2022 ($ BILLION) 29
TABLE 17 GLOBAL STD DIAGNOSTIC MARKET BY PHONE CHIPS 2012-2022 ($ BILLION) 29
TABLE 18 GLOBAL STD DIAGNOSTIC MARKET BY MICROFLUIDICS 2012-2022 ($ BILLION) 29
TABLE 19 GLOBAL STD DIAGNOSTIC MARKET BY 2012-2022 ($ BILLION) IMMUNOCHROMATOGRAPHIC TESTS (ICTS) 29
TABLE 20 GLOBAL STD DIAGNOSTIC MARKET BY RAPID DIAGNOSTIC KITS 2012-2022 ($ BILLION) 29
TABLE 21 GLOBAL STD DIAGNOSTIC MARKET BY REGION 2012-2022 ($ BILLION) 30
TABLE 22 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
TABLE 23 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 30
TABLE 24 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
TABLE 25 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
TABLE 26 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
TABLE 27 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
TABLE 28 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
TABLE 29 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
TABLE 30 MEXICO MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
TABLE 31 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
TABLE 32 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 30
TABLE 33 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
TABLE 34 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
TABLE 35 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
TABLE 36 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
TABLE 37 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
TABLE 38 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 39 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 40 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 41 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 42 ITALY MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 31
TABLE 43 ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 44 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 31
TABLE 45 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 46 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 31
TABLE 47 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 48 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 49 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 50 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 51 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 52 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 53 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 31
TABLE 54 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 55 AUSTRALIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 32
TABLE 56 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 32
TABLE 57 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 32
TABLE 58 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
TABLE 59 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 32
TABLE 60 SOUTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 32

FIGURE 1 MARKET SHARE BY REGIONS 32
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
FIGURE 4 MEXICO MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
FIGURE 5 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
FIGURE 6 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
FIGURE 7 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
FIGURE 8 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
FIGURE 9 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
FIGURE 10 ITALY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
FIGURE 11 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 12 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 13 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 14 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 15 AUSTRALIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 16 REST OF THE WORLD MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 17 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33
FIGURE 18 SOUTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 33

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)